Top-Rated StocksTop-RatedNASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free SNDX Stock Alerts $20.79 -0.18 (-0.86%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$20.65▼$21.1750-Day Range$20.49▼$24.5752-Week Range$11.22▼$25.34Volume367,583 shsAverage Volume1.14 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice Target$34.42 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Syndax Pharmaceuticals alerts: Email Address Syndax Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside65.5% Upside$34.42 Price TargetShort InterestBearish11.32% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment-0.05Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.70) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.02 out of 5 starsMedical Sector353rd out of 907 stocksPharmaceutical Preparations Industry156th out of 421 stocks 3.5 Analyst's Opinion Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSyndax Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.32% of the outstanding shares of Syndax Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently increased by 15.49%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Syndax Pharmaceuticals is -1.12. Previous Next 1.1 News and Social Media Coverage News SentimentSyndax Pharmaceuticals has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Syndax Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Syndax Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($3.70) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Read More SNDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNDX Stock News HeadlinesApril 22, 2024 | americanbankingnews.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 18, 2024 | americanbankingnews.comFinancial Analysis: Syndax Pharmaceuticals (NASDAQ:SNDX) and Biofrontera (NASDAQ:BFRI)April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 10, 2024 | finance.yahoo.comSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology ForumApril 10, 2024 | prnewswire.comSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology ForumApril 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)April 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth ProspectsApril 8, 2024 | prnewswire.comSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary SessionApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 6, 2024 | finanznachrichten.deSyndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 3, 2024 | msn.comCrinetics Pharmaceuticals gains amid pitch at Sohn charity conference (update)March 29, 2024 | msn.com20 European Cities with Highest Weed ConsumptionMarch 29, 2024 | msn.comThis longevity company is letting you check the ‘credit score’ for your health. Here are my surprising results and biological ageMarch 28, 2024 | msn.comSyndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDAMarch 28, 2024 | finance.yahoo.comSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid LeukemiaMarch 28, 2024 | seekingalpha.comSyndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite HopeMarch 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Quanterix (QTRX)March 27, 2024 | marketwatch.comSyndax Says Revumenib NDA Granted FDA Priority ReviewMarch 27, 2024 | markets.businessinsider.comSyndax Announces FDA Priority Review Of NDA For Revumenib For Treatment Of R/R KMT2Ar Acute LeukemiaMarch 27, 2024 | msn.comFDA grants priority review for Syndax leukemia drug, sets action dateMarch 27, 2024 | finance.yahoo.comSyndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute LeukemiaMarch 18, 2024 | finanznachrichten.deSyndax Pharmaceuticals: Syndax Announces Appointment of Steven Closter as Chief Commercial OfficerMarch 18, 2024 | finance.yahoo.comSyndax Announces Appointment of Steven Closter as Chief Commercial OfficerMarch 16, 2024 | finance.yahoo.comSNDX Apr 2024 17.500 putMarch 13, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn SituationMarch 6, 2024 | markets.businessinsider.comBuy Rating for Syndax Pharmaceuticals Amidst Strategic Progress and Regulatory MilestonesMarch 3, 2024 | finance.yahoo.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call TranscriptSee More Headlines Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/24/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SNDX CUSIPN/A CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees184Year FoundedN/APrice Target and Rating Average Stock Price Target$34.42 High Stock Price Target$45.00 Low Stock Price Target$23.00 Potential Upside/Downside+65.5%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.88% Return on Assets-44.00% Debt Debt-to-Equity RatioN/A Current Ratio10.00 Quick Ratio10.00 Sales & Book Value Annual Sales$139.71 million Price / Sales12.64 Cash FlowN/A Price / Cash FlowN/A Book Value$6.53 per share Price / Book3.18Miscellaneous Outstanding Shares84,965,000Free Float81,481,000Market Cap$1.77 billion OptionableOptionable Beta1.03 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Michael A. Metzger M.B.A. (Age 53)CEO & Director Comp: $1.1MDr. Peter Ordentlich B.Sc. (Age 55)Ph.D., Co-Founder & Chief Scientific Officer Dr. Richard A. Heyman Ph.D. (Age 67)Co-Founder Dr. Ronald M. Evans Ph.D. (Age 75)Co-Founder, Advisor and Chair of Scientific Advisory Board Dr. Michael Downes Ph.D.Co-FounderSharon KlahreVice President of Investor Relations & CommunicationsMr. Kevin McManus (Age 55)Chief People Officer Dr. Joseph Paul Eder M.D.Member of Scientific Advisory Board & Chief Medical OfficerDr. Anjali Ganguli Ph.D. (Age 47)Chief Business Officer Comp: $450.58kMr. Steven ClosterChief Commercial OfficerMore ExecutivesKey CompetitorsAgios PharmaceuticalsNASDAQ:AGIOSchrödingerNASDAQ:SDGRCatalyst PharmaceuticalsNASDAQ:CPRXStructure TherapeuticsNASDAQ:GPCRAmneal PharmaceuticalsNASDAQ:AMRXView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 134,037 shares on 4/24/2024Ownership: 0.327%Mesirow Financial Investment Management Inc.Sold 3,706 shares on 4/19/2024Ownership: 0.014%Diversified Trust CoBought 15,523 shares on 4/18/2024Ownership: 0.018%Kingdon Capital Management L.L.C.Bought 746,293 shares on 3/18/2024Ownership: 0.878%Vanguard Group Inc.Bought 718,051 shares on 3/11/2024Ownership: 5.103%View All Insider TransactionsView All Institutional Transactions SNDX Stock Analysis - Frequently Asked Questions Should I buy or sell Syndax Pharmaceuticals stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SNDX shares. View SNDX analyst ratings or view top-rated stocks. What is Syndax Pharmaceuticals' stock price target for 2024? 10 brokerages have issued twelve-month price targets for Syndax Pharmaceuticals' shares. Their SNDX share price targets range from $23.00 to $45.00. On average, they predict the company's share price to reach $34.42 in the next twelve months. This suggests a possible upside of 65.5% from the stock's current price. View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts. How have SNDX shares performed in 2024? Syndax Pharmaceuticals' stock was trading at $21.61 at the beginning of 2024. Since then, SNDX stock has decreased by 3.8% and is now trading at $20.79. View the best growth stocks for 2024 here. When is Syndax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our SNDX earnings forecast. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its earnings results on Tuesday, February, 27th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.99) by $0.01. During the same period in the previous year, the company posted ($0.62) EPS. What ETFs hold Syndax Pharmaceuticals' stock? ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), ALPS Medical Breakthroughs ETF (SBIO), Simplify Propel Opportunities ETF (SURI), SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Simplify Health Care ETF (PINK). What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU). When did Syndax Pharmaceuticals IPO? Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.33%), Diversified Trust Co (0.02%) and Mesirow Financial Investment Management Inc. (0.01%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith A Goldan, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich, Pierre Legault and William Meury. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SNDX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
